A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS WITH INTRACEREBRAL HEMORRHAGE (ICH)

Registry ID

B2341002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA INC

Start date

2017-04-19

Last update

2016-03-30

Conditions

• INTRACEREBAL HEMORRAGE

Related clinical trials

• EDOXABAN FOR INTRACRANIAL HEMORRHAGE SURVIVORS WITH ATRIAL FIBRILLATION
• NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION AND PREVIOUS INTRACEREBRAL HEMORRHAGE STUDY
• MINIMALLY INVASIVE SURGERY PLUS RT-PA FOR ICH EVACUATION MISTIE

View on source registry